WIBP - COVID-19 Vaccine Expansion Project: Animal Research Facility

Integrated EPC for High-Standard Bio-Safety Research & Global Vaccine Supply Support

Scale: 9,000 sqm

Project Overview

A Critical "Safety Barrier" for Global Vaccine Supply

Engineering the high-precision environment required for the safety evaluation and efficacy testing of inactivated COVID-19 vaccines.

AIPURE delivered the core animal research and production facility for the Wuhan Institute of Biological Products (WIBP), a pivotal component of the national vaccine production base. These high-cleanliness workshops (Class 7) maintain constant temperature and humidity to support pre-clinical in-vivo efficacy and safety assessments. As a vital link in the vaccine supply chain, this facility was essential in expanding production capacity to meet urgent global demand.

Technical Highlights

  • 75-Day Delivery: Completion of a complex, large-scale facility in just 75 days—compressing a typical one-year construction cycle.

  • Class 7 Cleanliness Standards: Implementation of high-precision sealing and air purification for animal research and production zones.

  • Massive Scale Coordination: Renovation of 9 existing workshops alongside construction of 3 new buildings.

  • Global Quality Recognition: The facility’s excellence enabled WIBP to receive Full Accreditation from AAALAC International in November 2025.

Engineering Challenges & Solutions

  • A “Race Against Time and Space”: To meet the urgent need for vaccine expansion, construction began seamlessly as vaccines were approved. We mobilized a specialized task force operating on a 24-hour shift rotation, minimising idle time between construction phases to complete the project within the 75-day window.

  • Precision Sealing for Verified Integrity: High-cleanliness animal rooms require verified airtightness. We utilized hollow return-air cleanwall panels and specialized rock-wool composite panels, performing meticulous sealing at every column, joint, and utility interface to ensure all sampling points meet the specified cleanliness benchmarks.

  • Advanced Zonal Airflow Management: To ensure stable and controllable airflow, we partitioned the cleanroom HVAC system into 8 independent zones. Each zone was equipped with its own AHU (Air Handling Unit), allowing for precise regulation of supply and exhaust volumes to maintain specific pressure gradients.

  • “Wartime” Supply Chain Security: Despite global supply chain disruptions, we pre-emptively secured inventories of critical purification materials and mechanical equipment. This proactive procurement ensured that peak construction was never delayed by material shortages.

Key Achievements

  • Expanded Capacity to 1 Billion Doses: The facility enabled WIBP to increase its annual COVID-19 vaccine capacity from 100 million to 1 billion doses, contributing to China National Biotec Group’s total capacity of over 5 billion doses.

  • International Compliance Milestones: The facility’s high-standard hardware led to full accreditation by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). This signifies that the facility meets the highest international standards for bio-pharmaceutical research.

  • Seamless Regulatory Handover: On 31 May 2020, the facility was fully completed and production-ready, achieving simultaneous compliance in both construction quality and biosafety hardware.

  • A Benchmark for Emergency EPC: This project demonstrates AIPURE’s superior ability to manage the dual challenges of extreme timelines and rigorous cleanliness requirements in mission-critical public health projects.

Why This Project Defines AIPURE

“Delivering international-grade biosafety at the speed of global necessity.”

The WIBP Vaccine Expansion project showcases AIPURE’s mastery in “Emergency High-Standard EPC.” By delivering a world-class animal research facility in record time—enabling the massive scale-up of life-saving vaccines—we prove that our technical standards and project management are built to meet the most critical challenges in global healthcare.

Project Conclusion

The WIBP COVID-19 Vaccine Expansion project is a landmark achievement in AIPURE’s history, demonstrating our unparalleled ability to execute mission-critical EPC projects under extreme time pressure. By completing a high-cleanliness, high-containment animal research facility in just 75 days, we proved that speed and safety can coexist through advanced engineering and rigorous coordination. This project was more than a construction feat; it was a race against time to secure the global vaccine supply. Today, this facility stands as a resilient “Safety Barrier,” supporting the continuous innovation and testing required to protect public health worldwide. At AIPURE, we don’t just build to specifications; we build to save lives.

VIEW MORE PROJECTS

Related Service

Cleanroom Consulting

Cleanroom Design

Construction

Product Manufacturing

Commissioning

Operation & Maintain

Contact Information

Global Sales & Technical Support

+86 15607108630

WhatsApp Support

+86 15607108630

China Headquarter Address

No 18 Finance Harbor 4th Road, Wuhan, China.

Request a Tailored Proposal

We respond to technical inquiries within 24 hours.

Scroll to Top